Literature DB >> 2514093

Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.

D Lawrence1, L Strandberg, T Grundström, T Ny.   

Abstract

Plasminogen activator inhibitor 1 (PAI-1) inhibits both tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) and, therefore, is an important regulator of plasminogen activation. We have developed eucaryotic and procaryotic expression systems for PAI-1 and characterized the recombinant glycosylated and non-glycosylated products, together with a non-recombinant natural control, produced in the histosarcoma cell line HT 1080. For eucaryotic expression, the PAI-1 cDNA was stably transfected into chinese hamster ovary cells (CHO cells), while procaryotic expression in Escherichia coli was examined after inserting the DNA sequence encoding the mature PAI-1 protein into an inducible expression vector. Recombinant PAI-1 from CHO cells was purified approximately 50-fold in two steps and was indistinguishable from natural PAI-1. Between 3% and 4% of total cellular protein in the procaryotic expression system consisted of PAI-1, from which it was purified approximately 30-fold, with yields of between 15% and 20%. This PAI-1 formed 1:1 complexes with uPA and also with the single- and two-chain forms of tPA. Kinetic analysis demonstrated that the procaryote-produced PAI-1 had an inhibitory activity towards all three forms of PA that resembled that of natural PAI-1 with association rate constants of approximately 10(7) M-1 s-1. In contrast to PAI-1 from eucaryotic cells, the PAI-1 from E. coli had an inherent activity equal to that of guanidine/HCl-activated natural PAI-1. The activity could not be increased by treatment with denaturants suggesting that the latent form of PAI-1 was absent. However, at 37 degrees C the procaryote-produced PAI-1 lost activity at the same rate as natural PAI-1, with approximately 50% of the activity remaining after 3 h. This activity could be partially restored by treatment with 4 M guanidine/HCl. E. coli-derived PAI-1, added to human plasma and fractionated by Sephacryl S-200 chromatography, eluted in two peaks that were similar to those obtained with guanidine-activated PAI-1 from eucaryotic cells, suggesting that it bound to the PAI-1-binding protein (vitronectin).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514093     DOI: 10.1111/j.1432-1033.1989.tb15238.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  17 in total

1.  The use of site-directed fluorophore labeling and donor-donor energy migration to investigate solution structure and dynamics in proteins.

Authors:  F Bergström; P Hägglöf; J Karolin; T Ny; L B Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Bypassing the kinetic trap of serpin protein folding by loop extension.

Authors:  H Im; H Y Ahn; M H Yu
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

Review 3.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

4.  The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.

Authors:  Yu-Ran Na; Hana Im
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

5.  Binding of tissue plasminogen activator to human endothelial cells. Importance of the B-chain as a ligand.

Authors:  X F Cheng; O Bäck; T K Nilsson; E Nylander Lundqvist; G Pohl; P Wallén
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

6.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

7.  Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins.

Authors:  Jonas Nascimento Conde; Emiliana Mandarano da Silva; Diego Allonso; Diego Rodrigues Coelho; Iamara da Silva Andrade; Luciano Neves de Medeiros; Joice Lima Menezes; Angela Silva Barbosa; Ronaldo Mohana-Borges
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

8.  Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.

Authors:  L Naldini; L Tamagnone; E Vigna; M Sachs; G Hartmann; W Birchmeier; Y Daikuhara; H Tsubouchi; F Blasi; P M Comoglio
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

Review 9.  Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.

Authors:  Manuel Yepes; Yena Woo; Cynthia Martin-Jimenez
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

10.  Transgenic overexpression of a stable Plasminogen Activator Inhibitor-1 variant.

Authors:  Abigail T Fahim; He Wang; Jining Feng; David Ginsburg
Journal:  Thromb Res       Date:  2008-09-05       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.